Why are Lipid Formulations Commonly Used to Enhance Bioavailability?

Various neurodegenerative processes result in the development of diseases like Alzheimer’s (AD), Parkinson’s (PD), amyotrophic lateral sclerosis (ALS), and, arguably, multiple sclerosis (MS). Despite years of research, drug discovery initiatives, and promising clinical trials, these diseases remain incurable. But recent studies have suggested common mechanisms underlying these pathologies. Atypical protein assembly resulting in plaque formation is a common pathological finding in both AD and PD, while neuronal death is a primary (ALS) or secondary (MS) hallmark of the disease. For a detailed look at the mechanisms that drive an array of neurodegenerative diseases, The Scientist is bringing together a panel of experts to share their research, discuss current therapeutic approaches, and offer their insights. Come engage with our panel and get the answers you seek.

This webinar will focus on the advantages of nasal powder formulations and on a non-human primate (NHP) model to quantify nose-to-brain delivery of a model compound, sumatriptan. The webinar will also compare pharmacokinetic advantages of nasal powders versus aqueous formulations, as well as in vitro results of nasal powder delivery.

Patient-centricity gets a lot of buzz, but what are the benefits of involving patients in the planning of a clinical trial?

This webinar will address these and other critical questions and will pave the way to strategic planning for compliance with the EU MDR. New product development teams will discover that the timeline for MDR is extremely limited compared to existing products on the market. Post-market surveillance teams will discover the implications of the Post-Market Clinical Follow-up requirement and the European Database on Medical Devices.